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Since its introduction in the 1970s, positron emission tomography (PET) has been used to investigate the basic 
biology and diagnosis of a diverse range of medical conditions in oncology, neurology, psychiatry, cardiology 
and inflammation. Indeed, to date, there have been well over 1500 biologically active compounds containing 
positron emitting isotopes such as [18F]fluorine, [11C]carbon or [13N]nitrogen described in the literature [1]. 
However, today one tracer, [18F]fluorodeoxyglucose (FDG), accounts for more than 90% of all clinical PET 
scans due to its broad applicability and availability. While other radiotracers have the potential to deliver a more 
fundamental understanding of the underlying biology of diseases and facilitate the development of new 
treatments, their production is limited to specialist hospitals and universities.  
At the core of the radiopharmaceutical synthesis process is the rapid incorporation of a positron-emitting isotope 
or synthon into a molecule of interest followed by product purification and formulation. Due to the short 
halflives of the radioisotopes used (18F: t½ = 110 min; 11C: t½ = 20.4 min; 13N: t½ = 10.0 min) it is advantageous to 
incorporate the radioisotope into the molecule of interest as late as possible in the synthetic sequence and have 
the production facility in close proximity to the PET scanning suite. However, several synthetic steps may be 
required to transform the radioactive isotope into a reactive form suitable for labeling [2] and the presence of 
multiple reactive groups on the precursor may also necessitate the use of protecting groups, which must be 
subsequently removed. Furthermore, since the radiotracers are typically administered intravenously, purification 
and reformulation processes must also be included to yield pharmaceutical grade materials. Consequently, large 
amounts of starting radioactivity may be required to compensate for radioactive decay, poor radiolabeling as 
well as deprotection efficiencies and losses during purification. Due to the high levels of penetrating gamma 
radiation emitted, specialist automated equipment, lead shielding, radiation containment and air-handling 
facilities are required, and the delivery of these imaging agents to the wider population remains a challenge. The 
future utilization of PET may be significantly enhanced, however, by improvements in reagent manipulation 
techniques, enabling production by nonspecialist radiochemists, and increased radiolabeling efficiency leading 
to a reduction in the quantities of starting activity required.  
Recently, great interest has been generated by the potential advantages of fluid-handling devices with feature 
sizes most conveniently measured in microns and total volumes typically in the nanoliter range, coined 
‘microfluidic reactors’ [3]. Initially applied to the areas of chemical and biological analysis, microfluidics has 
enjoyed a surge in popularity in the area of radiochemical synthesis due to inherent advantages associated with 
miniaturization, which correlate closely with the characteristic deficiencies in conventional macroscale 
radiosyntheses. Microfluidic reactors have intrinsically high surface area to volume ratios and short mixing 
distances, which culminate in extremely efficient mass and heat transfer, increasing reaction efficiency and 
enabling a significant reduction in processing time. An enhancement in reaction rates may also allow a reduction 
in precursor, solvent and reagent loading, which together can lead to a decrease in the degree of isotopic dilution 
[4]. The specific activity, the ratio of radioactively labeled product to its nonradioactive equivalent (e.g., 11C vs 
12C), is of particular importance in radiosyntheses that employ very short half-life isotopes [5]. Compared with 
conventional synthesis methodologies, decreased technical handling associated with microfluidic systems is, in 
principle, an attractive way to produce higher yielding syntheses. Furthermore, by reducing intrinsic length 
scales to less than those typically required for positron annihilation, radiolytic degradation of the 
radiopharmaceutical could be significantly reduced [6].  
Initially, microfluidic reactors were the domain of specialists in the field due to the precision fabrication 
methods, complicated fluid dynamics and technically challenging micro to macro-scale interfacing. Recently 
however, microfluidic reactors are increasingly becoming commercially available as standalone or modular 
devices. For the rapid screening of microfluidic radiolabeling conditions, a widely adopted strategy is to employ 
conventional scale laboratory automation for reagent handling, concentration and reformulation and to employ a 
microfluidic channel for the radiolabeling step only [7]. Microfluidic devices that operate in this fashion are 
known as flow-through or continuous-flow devices, where the reaction time is determined by the dimensions of 
the capillary and the flow rate. This technique does not require that the user have any specialist knowledge of 
microfluidic design or operation, and by limiting the number of microfluidic interfaces to that of a single 
capillary, rapid instigation and method development is facilitated [8–10]. 
However, the amalgamation of simple microscale channels and conventional automation techniques fails to 
address losses associated with macroscale syringe and fluidic connection dead volumes. In addition, despite the 
reaction volume being reduced by several orders of magnitude, no reduction in equipment footprint or 
infrastructure requirement is achieved. Furthermore, despite the improved mass and heat transfer efficiencies 
provided by microfluidics, benefits to radiosynthesis are not always realized. Where a radiolabeling method 
exhibits particularly slow reaction kinetics, improvements in mass and heat transfer may fail to offer yield 
improvements due to a required minimum reaction time [11]. For reactions of this type, a microfluidic device can 
be operated in a stopped-flow or batch mode [12]. Batch mode devices typically contain a greater degree of 
miniaturization than flow-through devices, potentially incorporating microvalves, micropumps and reagent 
storage on a single, fully integrated device [13]. With reaction chamber volumes measured in nanoliters, working 
with valuable reagents, such as peptides and antibodies, is simplified significantly, reducing losses and precursor 
cost per synthesis [14]. In contrast to the hybrid automation–microfluidic flow-through reaction systems, these 
fully integrated miniaturized synthesis devices offer significant reductions in shielding requirements due to their 
considerably reduced footprint. Microfluidic devices of this type are most frequently fabricated from polymers 
such as polydimethylsiloxane through micro-molding and lamination techniques. The application of mass 
production techniques, such as microinjection molding and hot embossing, may also enable microfluidic devices 
to offer a high degree of regulatory compliance through disposability commonly found in polymeric medical 
devices. However, with typical cyclotron liquid and gas target volumes ranging from less than 1 to several 
hundred milliliters, and formulated intravenous solutions ranging from 1 to 10 ml, devices of this nature are 
currently most suited to preclinical applications. Consequently, advances in methods for concentrating 
radiolabeled cyclotron products, as well as techniques for the purification and formulation of syntheses, are 
required. These must be further developed to interface with microfluidic systems to make this technology more 
accessible for clinical applications [15].  
The substitution of conventional automated radiosysnthesis equipment for microfluidic reactors alone cannot 
reduce the manufacturing costs of PET tracers sufficiently to enable its expansion to become an everyday 
imaging technique such as MRI or CT. Indeed, the application of miniaturization and flow-through synthetic 
techniques are not new to radiochemistry. Radiolabeling with [11C]methyl iodide within a stainless steel loop is 
a classic example of a biphasic reaction in a quasi-microfluidic channel, which can be utilized to obtain a 
number of radiotracers in high yield [16]. Furthermore, the reaction of [18F]fluoride trapped on functionalized 
polystyrene anion exchange ‘Merrifield’ resin packed in narrow bore tubing was, for a period, the de facto 
method for the manufacture of [18F]FDG [17]. 
It is clear, therefore, that the miniaturization of instrumentation for radiotracer synthesis offers significant 
advantages to the radiochemist in increases of reaction efficiency, and reduced development time and cost. 
Since automated synthesis units for the production of PET radiotracers became commercially available, the 
development and optimization of reaction variables (time, temperature, concentrations and so forth) has been 
largely left to the radiochemistry expertise of the end-users. This is desirable in a research setting or where 
flexibility of system operation is required. However, with the expansion of the availability of PET and the lack 
of suitable PET radiochemistry expertise, synthesis device manufacturers are increasingly developing robust 
synthetic sequences that can be exported to the PET laboratories for use ‘as is’. If the mainstream use of 
microfluidic technology is to become commonplace, the manufacturers of these devices will be looked to from 
many quarters of the PET community to take on similar levels of validation and optimization of processes that 
would require little or no further optimization by the end user.  
The universal applicability of microfluidics to PET tracer synthesis remains unsolved however, where issues of 
integration, slow-reaction kinetics and ability to process useful patient doses continue to present significant 
challenges. In addition to miniaturizing radiosynthesis, the infrastructure costs associated with the isotope 
generating cyclotron are also being investigated through the development of miniaturized cyclotrons [18]. By 
combining these two complementary technologies, the number of hospitals and institutions able to offer both 
commonly available tracers such as [18F]FDG, as well as enabling research with new and exciting radioligands, 
is set to expand significantly in the next few years and may usher in a new era in PET as a widespread clinical 
tool for the study of human physiology.  
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